AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29059359 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic as the toxic constituent, presence of an evocative image, FDA as the source
Number of subjects: 1669
Study 29059359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead as the toxic constituent, presence of an evocative image, FDA as the source
Number of subjects: 1669
Study 29059359 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic as the toxic constituent, absence of an evocative image, FDA as the source
Number of subjects: 1669
Study 29059359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead as the toxic constituent, absence of an evocative image, FDA as the source
Number of subjects: 1669
Study 29059359 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic as the toxic constituent, presence of an evocative image, no source
Number of subjects: 1669
Study 29059359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead as the toxic constituent, presence of an evocative image, no source
Number of subjects: 1669
Study 29059359 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic as the toxic constituent, absence of an evocative image, no source
Number of subjects: 1669
Study 29059359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead as the toxic constituent, absence of an evocative image, no source
Number of subjects: 1669
Study 28330908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy intervention (3 servings/d equivalent to ∼900 mg Ca/d)
Number of subjects: 240
Study 28330908 — intervention group
Group type: COMPARATOR
Intervention: Control (usual intake, achieving 1000 mg Ca/d)
Number of subjects: 240
Study 25908673 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient set-up with an automated NIV device
Number of subjects: 82
Study 25908673 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient set-up with nurse-led initiation of NIV
Number of subjects: 82
Study 25908673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 24151281 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-knee plaster of Paris casting
Number of subjects: 26
Study 24151281 — intervention group
Group type: COMPARATOR
Intervention: Below-knee plaster of Paris casting
Number of subjects: 26
Study 21435608 — intervention group
Group type: EXPERIMENTAL
Intervention: JOSTENT polytetrafluoroethylene (PTFE) stent-graft
Number of subjects: 243
Study 21435608 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 243
Study 19711453 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cells (105/kg)
Number of subjects: 17
Study 19711453 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cells (5 × 105/kg)
Number of subjects: 17
Study 19711453 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cells (106/kg)
Number of subjects: 17
Study 19711453 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 17526170 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Xiaoyao Decoction (MXD) combining clomipramine 25‐50 mg/d
Number of subjects: 105
Study 17526170 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine 75‐225 mg/d alone
Number of subjects: 105
Study 15316501 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 11981102 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 11981102 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dose-adjusted UFH
Number of subjects: 0
Study 9766458 — intervention group
Group type: EXPERIMENTAL
Intervention: Position change to left lateral position
Number of subjects: 42
Study 9766458 — intervention group
Group type: EXPERIMENTAL
Intervention: Position change to right lateral position
Number of subjects: 42
Study 9766458 — intervention group
Group type: EXPERIMENTAL
Intervention: Position change to supine position
Number of subjects: 42
Study 9766458 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2
Number of subjects: 42
Study 9766458 — intervention group
Group type: EXPERIMENTAL
Intervention: DO2
Number of subjects: 42
Study 7882602 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril 2.5 mg/day
Number of subjects: 17
Study 7882602 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 3257670 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose treatment (trimethoprim, 320 mg and sulfamethoxazole, 1600 mg)
Number of subjects: 255
Study 3257670 — intervention group
Group type: COMPARATOR
Intervention: 10-day treatment (trimethoprim, 160 mg and sulfamethoxazole, 800 mg, twice daily)
Number of subjects: 255
Study 3257670 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose treatment
Number of subjects: 255
Study 3257670 — intervention group
Group type: COMPARATOR
Intervention: 10-day treatment
Number of subjects: 255
Study 31359499 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily plus a four-drug regimen (amoxicillin, clarithromycin, bismuth, and esomeprazole) for 14 weeks
Number of subjects: 220
Study 31359499 — intervention group
Group type: COMPARATOR
Intervention: Four-drug regimen (amoxicillin, clarithromycin, bismuth, and esomeprazole) for 14 days
Number of subjects: 220
Study 31359499 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin plus four-drug regimen
Number of subjects: 220
Study 29205707 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive voice training (IVT)
Number of subjects: 20
Study 29205707 — intervention group
Group type: COMPARATOR
Intervention: Longer-term traditional voice training (TVT)
Number of subjects: 20
Study 27613357 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg oral dose prior to RAPN
Number of subjects: 30
Study 27613357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25298158 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular psychotherapy plus a web-based depression program ('deprexis')
Number of subjects: 800
Study 25298158 — intervention group
Group type: COMPARATOR
Intervention: Regular psychotherapy
Number of subjects: 800
Study 22079914 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdermabrasion treatment sessions (maximum 20 sessions over the course of a year)
Number of subjects: 0
Study 22079914 — intervention group
Group type: COMPARATOR
Intervention: Control scar (nontreated)
Number of subjects: 0
Study 22079914 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdermabrasion treatment
Number of subjects: 0
Study 20419572 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive condition
Number of subjects: 610
Study 20419572 — intervention group
Group type: COMPARATOR
Intervention: Nonincentive condition
Number of subjects: 610
Study 17279844 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of angry expressions on male faces
Number of subjects: 0
Study 17279844 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of happy expressions on female faces
Number of subjects: 0
Study 17279844 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrally expressive faces
Number of subjects: 0
Study 15644543 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 300
Study 15644543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus stent
Number of subjects: 300
Study 15644543 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel stent
Number of subjects: 300
Study 12111597 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 18
Study 12111597 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily for 7 days)
Number of subjects: 18
Study 12111597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12111597 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and Azithromycin
Number of subjects: 18
Study 10594490 — intervention group
Group type: EXPERIMENTAL
Intervention: Four times a day placebo regimen
Number of subjects: 3325
Study 10594490 — intervention group
Group type: COMPARATOR
Intervention: Twice a day placebo regimen
Number of subjects: 3325
Study 9122001 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH test (0.4 mg i.v.)
Number of subjects: 39
Study 9122001 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH and TRH with naloxone (2 mg i.v.)
Number of subjects: 39
Study 9122001 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone during TRH test
Number of subjects: 39
Study 1678705 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (0.15 mg kg‐1)
Number of subjects: 30
Study 1678705 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 30
Study 6410436 — intervention group
Group type: EXPERIMENTAL
Intervention: Community psychiatric nurses (CPN) as the main therapist
Number of subjects: 0
Study 6410436 — intervention group
Group type: COMPARATOR
Intervention: Routine out‐patient psychiatrist follow‐up
Number of subjects: 0
Study 29855319 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalizing diet (BASE)
Number of subjects: 11
Study 29855319 — intervention group
Group type: COMPARATOR
Intervention: Acidizing diet (ACID)
Number of subjects: 11
Study 26975417 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training (40 min per day, 2 times a week for 8 weeks)
Number of subjects: 32
Study 26975417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no balance training)
Number of subjects: 32
Study 26975417 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 32
Study 24748218 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic inflammation in benign prostate tissue
Number of subjects: 400
Study 22741259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pine needle moxibustion (group A)
Number of subjects: 43
Study 22741259 — intervention group
Group type: COMPARATOR
Intervention: Medicated thread moxibustion of Zhuang medicine (group B)
Number of subjects: 43
Study 20224376 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIVA method (n = 167)
Number of subjects: 501
Study 20224376 — intervention group
Group type: COMPARATOR
Intervention: Stripping with clinic marking (n = 167)
Number of subjects: 501
Study 20224376 — intervention group
Group type: COMPARATOR
Intervention: Stripping with duplex marking (n = 167)
Number of subjects: 501
Study 17365543 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-modelling intervention (viewing oneself perform an adaptive behaviour)
Number of subjects: 33
Study 17365543 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-observation intervention (viewing oneself perform at current skill level)
Number of subjects: 33
Study 17365543 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical practice only)
Number of subjects: 33
Study 16373264 — intervention group
Group type: EXPERIMENTAL
Intervention: ACIST injection system (n=252)
Number of subjects: 450
Study 16373264 — intervention group
Group type: COMPARATOR
Intervention: Manual contrast injection (control; n=198)
Number of subjects: 450
Study 11973193 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 120
Study 11973193 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 120
Study 11593638 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIG) injected during pregnancy
Number of subjects: 48
Study 11593638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBIG injection)
Number of subjects: 48
Study 7598419 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extrapleural intercostal nerve block combined with opiate and non-steroidal anti-inflammatory drug premedication
Number of subjects: 56
Study 7598419 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extrapleural intercostal nerve block
Number of subjects: 56
Study 7598419 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective perioperative analgesia
Number of subjects: 56
Study 7598419 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero pain score, complete preservation of preoperative lung function, prevention of the stress response to trauma
Number of subjects: 56
Study 2089821 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (n = 20)
Number of subjects: 30
Study 2089821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 30
Study 419164 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dosages of psychotropic drugs (neuroleptics, antidepressants, anxiolytics, psychostimulants)
Number of subjects: 75
Study 419164 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 75
Study 30112603 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 98
Study 30112603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CBT)
Number of subjects: 98
Study 27633728 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectively-measured outdoor time
Number of subjects: 192
Study 27633728 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps-per-day
Number of subjects: 192
Study 26217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic goal reminders (text or email)
Number of subjects: 76
Study 26217929 — intervention group
Group type: COMPARATOR
Intervention: No electronic goal reminders
Number of subjects: 76
Study 26217929 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic goal reminders at both visits
Number of subjects: 76
Study 23507124 — intervention group
Group type: EXPERIMENTAL
Intervention: High lactate levels at the end of surgery (3.6 mmol/L)
Number of subjects: 502
Study 23507124 — intervention group
Group type: EXPERIMENTAL
Intervention: High lactate levels immediately after ICU admission (0 hour) (4.4 mmol/L)
Number of subjects: 502
Study 23507124 — intervention group
Group type: EXPERIMENTAL
Intervention: High lactate levels 6 hours after ICU admission (4.0 mmol/L)
Number of subjects: 502
Study 23507124 — intervention group
Group type: EXPERIMENTAL
Intervention: High lactate levels 12 hours after ICU admission (2.3 mmol/L)
Number of subjects: 502
Study 23507124 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 502
Study 23507124 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) lower than 40%
Number of subjects: 502
Study 23507124 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher EuroSCORE
Number of subjects: 502
Study 23507124 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 502
Study 23507124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate levels 6 hours after ICU admission
Number of subjects: 502
Study 21195256 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad-helix appliance
Number of subjects: 99
Study 21195256 — intervention group
Group type: EXPERIMENTAL
Intervention: Expansion plate
Number of subjects: 99
Study 21195256 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 99
Study 19188877 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisture chamber (Q6H lubrication, eyelid closure and moisture chamber)
Number of subjects: 207
Study 19188877 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Q6H lubrication and eye closure)
Number of subjects: 207
Study 19188877 — intervention group
Group type: COMPARATOR
Intervention: Both eyes (control and treatment)
Number of subjects: 207
Study 19188877 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 207
Study 17409323 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 8468
Study 17409323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8468
Study 15342805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus radiation therapy
Number of subjects: 636
Study 15342805 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 636
Study 11773946 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic therapies (anti-tumour necrosis factor-alpha, interleukin-10, interleukin-11, anti-integrin antibody, antisense intercellular adhesion molecule-1 oligonucleotide)
Number of subjects: 0
Study 11773946 — intervention group
Group type: COMPARATOR
Intervention: Older therapies (5-acetylsalicylic acid, corticosteroids, azathioprine)
Number of subjects: 0
Study 9553680 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg talinolol
Number of subjects: 97
Study 9553680 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg talinolol
Number of subjects: 97
Study 9553680 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg talinolol
Number of subjects: 97
Study 9553680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 9553680 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg talinolol (twice daily)
Number of subjects: 97
Study 8713783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (NM)
Number of subjects: 0
Study 8713783 — intervention group
Group type: COMPARATOR
Intervention: Control (Heparin alone)
Number of subjects: 0
Study 2282090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin therapy
Number of subjects: 14
Study 7211918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous heparin therapy
Number of subjects: 0
Study 7211918 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin therapy
Number of subjects: 0
Study 30576246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GH bolus
Number of subjects: 18
Study 30576246 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline bolus
Number of subjects: 18
Study 30576246 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 h of fasting
Number of subjects: 18
Study 27785646 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive DVD educational tool
Number of subjects: 2
Study 27785646 — intervention group
Group type: COMPARATOR
Intervention: Arthritis Research UK leaflet
Number of subjects: 2
Study 26526385 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF BID (240 mg, twice daily)
Number of subjects: 2301
Study 26526385 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF TID (240 mg, three times daily)
Number of subjects: 2301
Study 26526385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2301
Study 24417529 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed (walking 1600 m prior to task)
Number of subjects: 34
Study 24417529 — intervention group
Group type: COMPARATOR
Intervention: Not primed (no prior walking)
Number of subjects: 34
Study 21681084 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness Workbook (WW) intervention
Number of subjects: 141
Study 21681084 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 141
Study 19487605 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone call from primary care practice within 72 hours of the initial PED visit
Number of subjects: 4246
Study 19487605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no follow-up phone call)
Number of subjects: 4246
Study 19487605 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone call from primary care practice
Number of subjects: 4246
Study 17304887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide, 200 microg once daily for 6 weeks
Number of subjects: 471
Study 17304887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 471
Study 15460498 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day pretreatment with lansoprazole 30 mg twice daily
Number of subjects: 76
Study 15460498 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 76
Study 11603907 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent ischaemia detected by multilead ECG monitoring
Number of subjects: 995
Study 11603907 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without recurrent ischaemia)
Number of subjects: 995
Study 10225769 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis fortnightly plus simvastatin 40 mg/day
Number of subjects: 0
Study 10225769 — intervention group
Group type: COMPARATOR
Intervention: Colestipol 20 g plus simvastatin 40 mg/day
Number of subjects: 0
Study 10225769 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 1392023 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 240mg twice daily for four weeks
Number of subjects: 80
Study 1392023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 3902375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flupirtine maleate (100 to 200 mg)
Number of subjects: 66
Study 3902375 — intervention group
Group type: COMPARATOR
Intervention: Oral pentazocine (50 to 100 mg)
Number of subjects: 66
Study 30585335 — intervention group
Group type: EXPERIMENTAL
Intervention: Octanoic acid
Number of subjects: 16
Study 30585335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30531821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried apricots (GI = 42 ± 5)
Number of subjects: 10
Study 30531821 — intervention group
Group type: EXPERIMENTAL
Intervention: Raisins (GI = 55 ± 5)
Number of subjects: 10
Study 30531821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultanas (GI = 51 ± 4)
Number of subjects: 10
Study 30531821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried apricots (GI = 57 ± 5) with displacement effect
Number of subjects: 10
Study 30531821 — intervention group
Group type: EXPERIMENTAL
Intervention: All dried fruits (displacing half carbohydrate in white bread)
Number of subjects: 10
Study 27435438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone (0.1 mg/kg) 10 minutes before surgery over 2 minutes
Number of subjects: 46
Study 27435438 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 46
Study 27435438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 24625502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 19
Study 24625502 — intervention group
Group type: COMPARATOR
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 19
Study 22951305 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1498
Study 22951305 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1498